ViewRay, Inc. (VRAY) has just announced MRIdian SMART (MR-guided stereotactic adaptive radiation therapy) study results related to the treatment of inoperable pancreatic cancer. The multi-center study results were delivered “as part of the Annual Meeting of the American Society for Radiation Oncology” in Chicago. As of 10:36 am EDT today, VRAY stock was 1.61% higher.
Survival and Quality of Life Improvements
Michael Chuong, M.D., presented the study results. “Findings showed longer median survival of 26 months” for patients with pancreatic cancer — the third leading cause of cancer death in the U.S. — compared with 12-15 months normally observed in patients “receiving chemotherapy and standard radiation therapy.” The 2-year overall survival rate hit 50 percent, doubling the expected 2-year rate of 20 percent with a lower dose of radiation.
Inoperable Pancreatic Cancer Outlook
Dr. Chuong was encouraged by the long-term survival data, pointing out that “some patients were still alive several years later with excellent quality of life.” The results are a big improvement compared to “historical outcomes from standard CT-guided radiation therapy."
“These findings offer hope for those facing an inoperable pancreatic cancer diagnosis and are bringing us one step closer to achieving our vision to create a world in which all patients with pancreatic cancer will thrive,” Julie Fleshman, president, and CEO of the Pancreatic Cancer Action Network, added.
VRAY has a Long-Term Technical Rank of 79. Find out what this means to you and get the rest of the rankings on VRAY!
ViewRay Inc is a radiation therapy and imaging technology company. It designs, manufactures and markets radiation therapy systems that provide real-time imaging during radiation treatment. Its product portfolio encompasses The MRIdian linac system, The MRIdian system, the Monte Carlo treatment planning system, etc. The company holds the license for its combination of MRI and radiation therapy technologies.